Analyst Sean Lee from H.C. Wainwright has initiated coverage on Senseonics (SENS, Financial), giving it a Buy rating and setting a price target of $1.10. The analyst highlights the company's standout product, Eversense 365, which is a groundbreaking continuous glucose monitoring system approved for a full year of use. This sets it apart from traditional systems that require replacement every 7 to 15 days. Currently, Senseonics is recognized as the fourth largest provider of such technology in the United States. The long duration of Eversense 365 offers a significant advantage in the glucose monitoring market, contributing to the positive outlook on SENS stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Senseonics Holdings Inc (SENS, Financial) is $2.00 with a high estimate of $2.00 and a low estimate of $2.00. The average target implies an upside of 282.04% from the current price of $0.52. More detailed estimate data can be found on the Senseonics Holdings Inc (SENS) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Senseonics Holdings Inc's (SENS, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Senseonics Holdings Inc (SENS, Financial) in one year is $1.16, suggesting a upside of 121.59% from the current price of $0.5235. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Senseonics Holdings Inc (SENS) Summary page.
SENS Key Business Developments
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Senseonics Holdings Inc (SENS, Financial) reported a 24% increase in net revenue for Q1 2025, reaching $6.3 million compared to $5 million in the prior year.
- The company announced the integration of its EverSense 365 continuous glucose monitor with SQL's Twist Automated Insulin Delivery System, enhancing patient experience through simplified insulin delivery.
- Senseonics Holdings Inc (SENS) has filed for CE mark approval for EverSense 365, with a European launch expected in the second half of 2025.
- The company has successfully transitioned many US payers to reimburse EverSense 365 for a full year, with Medicare updating its physician fee schedule to support this change.
- Senseonics Holdings Inc (SENS) has made progress in its pipeline products, Gemini and Freedom, aiming to enhance patient experience with innovative features like a built-in battery and Bluetooth communication.
Negative Points
- The ongoing restructuring at Mercy Health Systems has paused new initiatives, impacting the rollout of EverSense with remote patient monitoring.
- Despite revenue growth, Senseonics Holdings Inc (SENS) reported a net loss of $14.3 million for Q1 2025, though this was an improvement from the previous year's loss.
- The company faces challenges in scaling manufacturing for EverSense 365, with limited scale affecting gross profit margins.
- There is a potential low single-digit impact on gross profit margins due to tariffs, as the company relies on a global supply chain with some components sourced from China.
- The integration work for the Twist Automated Insulin Delivery System is still ongoing, with verification and validation needed on the pump side to meet the Q3 timeline.
